计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
A potent inhibitor of Cox-1 and Cox-2
Information
Flurbiprofen is a member of the phenylalkanoic acid derivative family of non-steroidal anti-inflammatory drugs (NSAIDs).
In vitro
Flurbiprofen effectively inhibits the growth of various tumor cells in a dose-dependent manner and causes a noticeable change in the progression of cells through cell cycle stages in tumor cell lines derived from medulloblastoma and glioblastoma multiforme. Flurbiprofen reduces the number of cells in G1 and G2, and significantly increases their numbers in S phase, suggesting that, Flurbiprofen accelerates G1/S entry, and/or delays cell exit from S to G2/M stages. Flurbiprofen causes a minor change in the RNA level of different cyclins, there is a significant decrease in the level of cyclin B protein upon flurbiprofen treatment.
In vivo
Flurbiprofen affords significant neuroprotection from ischemic injury as evidenced by reduction in cerebral infarct volume and neurobehavioral deficit. Flurbiprofen significantly reduces an early calcium dependent rise in levels of nitrite and MDA in ischemic brain regions of rats. Flurbiprofen also reduces the proteolytic products (SBDPs) caused by ischemic activation of calcium dependent protease calpain. Flurbiprofen (5 mg/kg and 10mg/kg) significantly attenuates brain ischemia/reperfusion injury in rats, as shown by a reduction in the infarct volume, neurological deficit scores and cell apoptosis. Flurbiprofen not only inhibits the expression of Bax protein and p-GSK-3β, but also increases the expression of Bcl-2 protein, the ratio of Bcl-2/Bax as well as the P-Akt level in rats.
Cell Data
cell lines:
Concentrations:
Incubation Time:
Powder Purity:≥99%
| ALogP | 4.2 |
|---|
H301: 吞咽会中毒
H315: 引起皮肤刺激
H319: 引起严重眼睛刺激
H335: 可能引起呼吸道刺激
H361: 怀疑破坏生育力或未出生的孩子